Revolutionary Collaboration between Sony and Cellares in Automated Cell Therapy
Sony and Cellares have recently announced a promising collaboration poised to transform cell therapy manufacturing through automation and advanced analysis technologies. This collaboration will integrate the flow cytometry-based sorting and analysis capabilities of Sony’s CGX10 system into Cellares’ Cell Shuttle™ automation platform, which is already well-known in the industry. This step is expected to create the world’s first truly automated cell therapy manufacturing system, significantly reducing costs and production time.
The Cell Shuttle itself is a platform designed to automate the entire cell therapy manufacturing process in a closed environment. The advantage of this platform is its capacity to produce up to 16 batches of cell therapy simultaneously, reducing the potential for contamination and human error, and capable of reducing production costs by up to 50% compared to traditional methods. With the integration of technology from Sony, especially in cell sorting and analysis, production efficiency is expected to increase rapidly, especially in therapies that rely on regulatory T cells (Treg) and hematopoietic stem cells (HSC).
Sony’s flow cytometry technology allows for high-precision cell sorting, even in closed system conditions. This integration also enables real-time monitoring of cell quality, which has a positive impact on the overall efficiency and scale of cell therapy production.
Potential Influence in the Industry
The integration of Sony’s technology into the Cell Shuttle will have a major impact on the cell therapy industry. This collaboration is not just about increasing scale, but also offers comprehensive automation that can accelerate the delivery of therapies from vein to vein, a crucial step in accelerating access to patient care. In this scenario, efficiency is key, and the ability to produce large batches simultaneously at a lower cost is very attractive to cell therapy developers around the world.
Sony’s CGX10 technology, already used by cell therapy development companies, shows that cell sorting is an important step in the production process. With integration into the Cell Shuttle platform, the two companies are paving the way for more efficient, safer, and more affordable production increases, creating unprecedented potential on a large scale.
Conclusion
This collaboration between Sony and Cellares reflects the future of cell therapy manufacturing, which is becoming increasingly automated and scalable. With Sony’s advanced cell sorting and analysis technology integrated into Cellares’ Cell Shuttle platform, we see a major leap in the scale, efficiency, and speed of cell therapy production, which not only accelerates patient care but also significantly reduces costs. The medical world is preparing to welcome a new era that is more efficient and innovative in producing cell therapies to meet global needs.
